BIRC5 (Baculoviral IAP repeat containing 5)

The studied compounds demonstrated promising biological activities, with QCS-h emerging as a lead candidate exhibiting broad-spectrum antimicrobial activity against both B. cereus, P. aeruginosa, and C. glabrata, with considerably lower IC50 values compared to the used standards, tetracycline and nystatin. The favorable ADME profiles further support the drug-like potential of these compounds. This integrative approach highlights the therapeutic promise of quinoline-sulfonamide-chalcone hybrids, particularly QCS-h, as multi-targeted agents for combating antimicrobial resistance and gastrointestinal malignancies, providing valuable insights for future rational drug design strategies.

Moreover, the system successfully enabled accurate detection of survivin mRNA in different cell lines and HPV16 in clinical cervical swab samples, showing strong concordance with qPCR gold standard methods. The PRA-Cas13a strategy leverages intrinsic self-processing assembly and autocatalytic signal amplification, addresses the critical issue of off-target cleavage inherent in conventional Cas13a systems while expanding the range of applicable targets, and demonstrates high specificity and point-of-care testing potential in cancer and viral diagnostics.

The expression of ATP1A1, survivin, and SMAC did not differ by sex or diet, although an upregulation trend in both ATP1A1 and survivin was noted in the male-HFD group. There is sexual dimorphism in the response to HFD during the transition from senescence to the apoptosis-first apoptotic switch in MASH progression.

In vivo studies support these findings, showing increased FoxO3a and decreased survivin in brain tissue sections from metformin-treated mice compared with untreated controls. These results suggest new possibilities for repurposing MET as an adjuvant treatment for GB.

The present study successfully prepared FA-TLUM, and the combination of FA-TLUM with ultrasonic targeted fragmentation technology significantly enhances the inhibitory effect on MCF-7 cell proliferation and promotes cellular apoptosis. Therefore, this technology is anticipated to offer novel approaches and concepts for clinical breast cancer treatment.

Survivin and HER-2 expression are significantly associated and serve as independent predictors of poor response to NACT in LABC patients. Evaluation of these biomarkers could be crucial in risk stratification and the personalization of therapy.

Although the FDA-approved combination of encorafenib and cetuximab provides clinical benefit in this population, only 22% of patients respond and most eventually develop resistance...Importantly, we demonstrate that addition of TVB3664 to the PLX8394 or encorafenib regimen significantly postpones development of resistance to BRAF-targeted therapy by inhibiting the cell cycle progression via a decrease in pRb (Ser780) and downregulation of E2F transcription factor and Cyclin D1 expression. Consistently, clinical data show that patients with BRAFV600E CRC who have high FASN expression in tumor tissues have higher expression of cell cycle-associated genes, including CDKs, E2F, CCDN1 (Cyclin D1), survivin, and MKI67. Collectively, these findings identify FASN-driven lipid metabolism as a critical mediator of resistance to BRAF-targeted therapy and suggest that incorporation of FASN inhibitors may enhance therapeutic efficacy and delay acquired resistance in BRAFV600E CRC.

Moreover, Z. jujuba increased pro-apoptotic factors caspas3 and caspase9. The results demonstrated the therapeutic potential of Z. jujuba in CRC through anti-proliferative, and anti-inflammatory properties, indicating its potential value in the treatment of CRC.

Unlike another CAR, SSR does not produce significant cytotoxicity against normal CD38+ tissues. Our study thus shows that SSR arming enhances targeting of antigenically heterogeneous cancers without compromising safety and selectivity of therapeutic T cells.

These interactions suggest that MRW constituents' function as non-nucleoside DNMT-1 inhibitors and ROS-immune modulators that disrupt oncogenic feedback loops and re-activate apoptotic pathways. Collectively, these findings identify MRW as a multi-target phytomedicine integrating ROS-mediated oxidative stress, epigenetic remodeling, and immune-apoptotic signaling, supporting its translational potential as a low-toxicity adjunct strategy to conventional pancreatic cancer therapies.

Additionally, they reduced the levels of survivin, SMAC, and tubulin, while increasing p53 expression in both in vitro and in vivo models. These findings highlight a novel strategy for targeting undruggable survivin using survivin-derived engineered peptides, offering promising therapeutic potential in cancer.